Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration

IF 3 3区医学 Q1 OPHTHALMOLOGY

Acta Ophthalmologica Pub Date : 2023-10-06 DOI:10.1111/aos.15783

Erik Vinge, Tomas Bro

{"title":"Treatment burden on patients receiving intravitreal anti-VEGF for wet age-related macular degeneration","authors":"Erik Vinge, Tomas Bro","doi":"10.1111/aos.15783","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>The aim of this study was to map the treatment burden for patients with wet age-related macular degeneration (wAMD).</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>Patients with ongoing treatment with anti-VEGF for wAMD at a Swedish eye unit underwent a survey about the time spent receiving treatment, caregiver assistance, way of transportation, self-rated vision and negative experiences associated with the treatment such as discomfort, anxiety or transportation problems. Information about current visual acuity, number of treatments and current treatment intervals were obtained from medical records.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study included 93 patients with an average age of 79.9 years, 68% were women. The average interval between treatments was 7.3 weeks, and 26% had active treatment in both eyes. On average, patients had to spend 2.7 h (2.4–2.9: 95% CI) per treatment and a caregiver assisted the patient in 58% of cases. Caregivers spent on average 2.6 h (2.5–2.8: 95% CI) per visit, and 19% needed to take time off work. The majority (91%) of patients did not experience any transportation problems associated with treatment. A multivariate logistic regression analysis showed a significantly lower odds ratio for discomfort with higher self-rated vision and a significantly higher odds ratio for discomfort with longer treatment intervals.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>Anti-VEGF treatment is an effective treatment for wAMD. However, the relatively short treatment intervals place a considerable burden on patients and their relatives regarding time. Although the patients in this study had to spend a lot of time to receive treatment, the majority did not experience any problems associated with treatment.</p>\n </section>\n </div>","PeriodicalId":6915,"journal":{"name":"Acta Ophthalmologica","volume":"102 4","pages":"478-482"},"PeriodicalIF":3.0000,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aos.15783","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Ophthalmologica","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/aos.15783","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

The aim of this study was to map the treatment burden for patients with wet age-related macular degeneration (wAMD).

Method

Patients with ongoing treatment with anti-VEGF for wAMD at a Swedish eye unit underwent a survey about the time spent receiving treatment, caregiver assistance, way of transportation, self-rated vision and negative experiences associated with the treatment such as discomfort, anxiety or transportation problems. Information about current visual acuity, number of treatments and current treatment intervals were obtained from medical records.

Results

The study included 93 patients with an average age of 79.9 years, 68% were women. The average interval between treatments was 7.3 weeks, and 26% had active treatment in both eyes. On average, patients had to spend 2.7 h (2.4–2.9: 95% CI) per treatment and a caregiver assisted the patient in 58% of cases. Caregivers spent on average 2.6 h (2.5–2.8: 95% CI) per visit, and 19% needed to take time off work. The majority (91%) of patients did not experience any transportation problems associated with treatment. A multivariate logistic regression analysis showed a significantly lower odds ratio for discomfort with higher self-rated vision and a significantly higher odds ratio for discomfort with longer treatment intervals.

Discussion

Anti-VEGF treatment is an effective treatment for wAMD. However, the relatively short treatment intervals place a considerable burden on patients and their relatives regarding time. Although the patients in this study had to spend a lot of time to receive treatment, the majority did not experience any problems associated with treatment.

Abstract Image

查看原文本刊更多论文

玻璃体内注射抗VEGF治疗湿性年龄相关性黄斑变性患者的治疗负担。

目的：本研究的目的是绘制湿性年龄相关性黄斑变性（wAMD）患者的治疗负担图，自我评定的视力和与治疗相关的负面体验，如不适、焦虑或交通问题。有关当前视力、治疗次数和当前治疗间隔的信息来自医疗记录。结果：该研究包括93名患者，平均年龄79.9岁 68%为女性。治疗之间的平均间隔时间为7.3 26%的患者双眼均接受了积极治疗。平均而言，患者需要花费2.7 h（2.4-2.9:95%置信区间），58%的病例由护理人员协助。护理人员平均花费2.6 h（2.5-2.8:95%置信区间），19%需要请假。大多数（91%）患者没有遇到任何与治疗相关的交通问题。多变量逻辑回归分析显示，自评视力越高，不适的比值比越低，治疗间隔越长，不舒服的比值比就越高。讨论：抗VEGF治疗是治疗wAMD的有效方法。然而，相对较短的治疗间隔给患者及其亲属带来了相当大的时间负担。尽管本研究中的患者必须花费大量时间接受治疗，但大多数患者没有遇到任何与治疗相关的问题。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Ophthalmologica 医学-眼科学

CiteScore

7.60

自引率

5.90%

发文量

433

审稿时长

6 months

期刊介绍： Acta Ophthalmologica is published on behalf of the Acta Ophthalmologica Scandinavica Foundation and is the official scientific publication of the following societies: The Danish Ophthalmological Society, The Finnish Ophthalmological Society, The Icelandic Ophthalmological Society, The Norwegian Ophthalmological Society and The Swedish Ophthalmological Society, and also the European Association for Vision and Eye Research (EVER). Acta Ophthalmologica publishes clinical and experimental original articles, reviews, editorials, educational photo essays (Diagnosis and Therapy in Ophthalmology), case reports and case series, letters to the editor and doctoral theses.